Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
about
Cytoreductive surgery in the era of targeted molecular therapyIs there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?The role of metastasectomy in renal cell carcinoma in the era of targeted therapy.Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma.Surgical management of metastatic adrenal tumors: Decision-making factors in imaging.Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.Breast metastasis from clear cell renal cell carcinoma.Cervical lymph node metastasis in chromophobe renal cell carcinoma: a case report and review of the literaturePercutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.8-year survival in a patient with several recurrences of renal cell carcinoma after radical nephrectomy.Metachronous contralateral testicular and bilateral adrenal metastasis of chromophobe renal cell carcinoma: a case report and review of the literatureCurrent management and future perspectives of metastatic renal cell carcinoma.New challenges in kidney cancer management: integration of surgery and novel therapies.Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma.22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinomaMetastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival.Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma.The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma.Cytoreductive nephrectomy in the era of targeted therapies: a review.State-of-the-art treatment of metastatic renal cell carcinoma.Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma.Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.Metastasectomy following incomplete response to high-dose interleukin-2.Survival of renal cell carcinoma metastatic to nonthyroid head and neck region: A systematic review.MiR-216a exerts tumor-suppressing functions in renal cell carcinoma by targeting TLR4.Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?Metastasis in renal cell carcinoma: Biology and implications for therapy.
P2860
Q26774134-2BBB9C20-0298-4CD8-A2D1-67674EC0CA9BQ28087518-0CC3BDD2-3766-4DEA-8F9B-065AE763083BQ34501462-B17A3DAD-5C26-40C3-817C-436FBB257436Q34661359-53D9EEEB-AA5F-4AF4-8C81-7FEE6BE5B09AQ35140867-80E8E6EE-7C2A-47FF-A0EE-77F5745BF94BQ36142417-B38878C8-5128-4D79-9ED1-F75F4FE032E1Q36344279-32585926-3C06-4B06-BF0E-192B78AE82AEQ37166992-E85AC107-B2D3-4AFA-80E4-FF7AFCC1FF36Q37239864-B1A23FEA-1672-40C1-B870-C9C01853CE01Q37398545-D7B4B854-5A0C-4F03-AFE7-AD8949A03151Q37508012-02C332BD-610B-4831-A256-5E43312E9A6CQ37579170-49DA8C6A-4F4A-4983-ACFB-0FD888B05BE9Q37742560-16FE6235-8200-4CA6-AC50-5D0980F5C7A2Q38214976-446717DD-5987-45FB-AB44-FF09F6B53E5FQ38381788-E5613E60-2B01-4240-BA41-2924D5BAFBA1Q38555877-0F4A9B99-9F31-4E93-863E-2805193CED62Q38674642-304CA884-2B9A-4F33-8159-04B33A23C1DCQ38805775-365AB0DF-F939-48D7-B3EF-F6D3F55650E1Q38880667-A20A3A5C-E576-43AF-B2CA-5E55505D33AEQ39136550-C91045BD-4A23-426C-91FD-DCCAE00896AEQ39216342-B1728844-04BE-4AD7-9C28-EA941D7D1232Q39975802-B90C0AB1-D570-4148-AE9E-10B4E62011DFQ40685017-4D6E700B-B895-45B7-BEF6-202A52CD8419Q40789843-43A0F1F5-C416-491E-BE7F-FFA4461A2F57Q40929096-A6578E3F-1E0E-4C8B-BBDF-D08094BD08F6Q41036577-88A69F12-1CB1-47EE-A36A-50FEFC644222Q47428650-AD6A245B-4C21-445E-98CC-1BA730936DCAQ47843599-4606ABCD-8114-445C-94A1-2044B9F4C57DQ52595047-984CC887-27B4-4160-8433-5AD8F7D730BFQ54323156-BD30FF57-3AC8-4AB0-8061-E754C7D6F983Q54936635-72EE5181-DA74-4F38-A31B-08E2D2F1E9B4
P2860
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Risk score and metastasectomy ...... ecurrent renal cell carcinoma.
@en
type
label
Risk score and metastasectomy ...... ecurrent renal cell carcinoma.
@en
prefLabel
Risk score and metastasectomy ...... ecurrent renal cell carcinoma.
@en
P2093
P2860
P1476
Risk score and metastasectomy ...... ecurrent renal cell carcinoma.
@en
P2093
Ofer Yossepowitch
Paul Russo
Scott E Eggener
Shilajit Kundu
P2860
P304
873-8; discussion 878
P356
10.1016/J.JURO.2008.05.006
P407
P577
2008-07-17T00:00:00Z